The tweet was deleted by the author.
But we saved everything 🙂.
Vertex Pharmaceuticals announces positive study results and trial enrollment after muted trading session
Vertex Pharmaceuticals announced positive Phase 2b results for its AMPLIFIED study and completed enrollment in a separate late-stage trial for APOL1-mediated kidney disease. The stock edges higher on the day, trading at $510.64.
VRTX price prediction
Current price:
$538.53
-4.0900
0.75%
Closed
11/13
Daily range
536.41
542.58
542.58
Weekly range
536.31
553.34
553.34
Loading...
Highlights
- Vertex Pharmaceuticals announced positive Phase 2b results for inaxaplin in patients with APOL1-mediated kidney disease and finished enrollment for its Phase 2/3 AMPLITUDE study.
- Interim data from the AMPLITUDE trial are expected in early 2027 and could support accelerated U.S. approval for APOL1-mediated kidney disease, affecting about 150,000 Americans.
- Vertex Pharmaceuticals stock edges higher on the day, trading at $510.64.
Vertex Pharmaceuticals announced positive Phase 2b results from the AMPLIFIED study of inaxaplin for people with APOL1-mediated kidney disease. The company also completed enrollment in its Phase 2/3 AMPLITUDE trial targeting the same condition. According to FinancialContent, interim analysis results from the AMPLITUDE trial are expected in early 2027 and could lead to accelerated approval in the U.S. As noted by Investing.com India, APOL1-mediated kidney disease affects about 150,000 people in the U.S.
View post on X Loading...
Support from oversold Stoch RSI as price holds above MA-200
Price is testing resistance from MA-50 at $511.12. The current structure is mixed, with shares trading below both the MA-20 and MA-50 while remaining above the MA-200. Stoch RSI is in oversold territory, which limits room for further downside and supports stabilization within this range.
Odds tilt to the downside as $511.12 remains unbroken
Traders should watch whether the price can clear resistance at $511.12. Shares have approached that level but have not managed a close above it. Even so, despite an emerging move higher over the past week that is not yet confirmed, there is a 43% probability of upside and a 57% probability of downside for the coming trading week, with an expected range between $503.9 and $517.37. A close above $511.12 would show buyers are willing to follow through, while a drop below $502.2 would demonstrate the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Earlier, analysts noted that Vertex Pharmaceuticals was experiencing near-term technical exhaustion, despite a constructive longer-term trend. The latest clinical trial updates add a new dimension to the outlook, with traders now closely watching whether shares can establish support above the MA-50 at $511.12 to confirm a potential shift in momentum.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Latest Vertex Pharmaceuticals News
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
